

Osteoporosis: risk assessment, treatment and prevention of fragility fractures Committee meeting 8

Date: 14/02/2024

Location: Virtual (Zoom)

Minutes: Final

Committee members present:		
Alison Tedstone (Chair)		(Present for notes 1 – 6)
Nicola Peel (Topic adviser)		(Present for notes 1 – 6)
Alison Ahmed		(Present for notes 1 – 6)
Irene Baker		(Present for notes 1 – 6)
Sherwin Criseno		(Present for notes 1 – 6)
Kay Morgan		(Present for notes 1 – 6)
Rachel Muir		(Present for notes 1 – 6)
Nicholas Pipkin		(Present for notes 1 – 6)
Stuart Ralston		(Present for notes 4 – 6)
Rajesh Varma		(Present for notes 1 – 6)
Karen Whitehead		(Present for notes 1 – 6)

In attendance:		
Annette Chalker	Systematic Reviewer	(Present for notes 1 – 6)
Sarah Glover	Information Specialist	(Present for notes 1 – 6)
Amber Hernaman	Project Manager	(Present for notes 1 – 6)
Bernard Higgins	Clinical advisor	(Present for notes 1 – 6)
Kate Lovibond	Senior Health Economist	(Present for notes 1 – 6)
Julie Neilson	Senior Systematic Reviewer	(Present for notes 1 – 5)
Muksitur Rahman	Health Economist	(Present for notes 1 – 6)
Carlos Sharpin	Guideline Lead	(Present for notes 1 – 6)
Hugo Pedder	TSU	(Present for notes 1 – 6)
Nicky Welton	TSU	(Present for notes 1 – 6)

Apologies:

Elaine Dennison	Committee member
Paul Hamilton	Committee member
Karen Knapp	Committee member
Iain Macleod	Committee member
Nick Stapes	Guideline Commissioning Manager

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the eight Osteoporosis guideline committee. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included.

- The treatment review approach
- Health economics drug resource estimates
- Risk assessment recommendations

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was risk assessment.

The Chair asked everyone to verbally declare any interests that had arisen since the last meeting. Declarations of interest forms were received from Karen Whitehead.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Karen Whitehead	Lay member	ART-TRANslations new art project – bringing new patient-centric/led research to life by artists – I’m involved as a patient working with researchers and an assigned artist to explain my lived experience of osteoporosis (& pregnancy associated osteoporosis) & once their new artwork is produced, I will then	Direct, non-financial professional and personal interests	Declare and participate.

		be presenting alongside them & attending events during 2024		
3. Minutes of last meeting				
Agreed.				
4. Treatment review approach				
<p>Kate Lovibond presented the TA history and guidance to the committee and Julie Neilson presented the protocol queries.</p> <p>Kate Lovibond provided information on doing a Network Meta-Analysis. Hugo Pedder from the TSU presented to the committee doing an NMA to explore the impact of treatments on risk of fractures.</p>				
5. Health Economics				
Claire Sloan presented the drug resource estimates to the committee.				
6. Recommendations				
Carlos Sharpin discussed the risk assessment recommendations and made edits to them on the day.				
7. AOB				
None.				

Date of next meeting: 26/03/2024

Location of next meeting: Zoom